Related Experiment Video

Updated: Oct 29, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Umair Majeed1, Rami Manochakian1, Yujie Zhao1

  • 1Division of Hematology and Medical Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.

Journal of Hematology & Oncology
|July 9, 2021
PubMed

Insights

Targeted therapies offer durable responses for non-small cell lung cancer (NSCLC) patients with specific mutations. This review covers recent advances and early clinical trials in personalized NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Lung cancer is a leading cause of cancer mortality globally.
  • Non-small cell lung cancer (NSCLC) constitutes 84% of lung cancer cases.
  • Targeted therapy provides durable responses for NSCLC patients with actionable mutations.

Purpose of the Study:

  • To review recent advances in targeted therapy for advanced NSCLC.
  • To focus on first-in-human and early phase I/II clinical trials.
  • To provide an up-to-date overview of current and emerging NSCLC targeted treatments.

Main Methods:

  • Literature review of recent advances in NSCLC targeted therapy.
  • Focus on early-phase clinical trials (Phase I/II).
  • Categorization of targeted agents by mechanism of action.

Main Results:

  • Personalized medicine is advancing rapidly in NSCLC treatment.
  • Targeted therapies are showing durable responses in subsets of patients.
  • Numerous early-phase clinical trials are investigating novel agents.

Conclusions:

  • Advances in molecular techniques enable personalized NSCLC treatment.
  • Targeted therapies represent a significant progress in managing advanced NSCLC.
  • Ongoing clinical trials are crucial for developing future treatment options.
Keywords:
Advanced NSCLCFirst-in-humanLung cancerPhase I/II clinical trialsTargeted therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
781
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
586
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K